BAIT
DOT1L
DOT1, KMT4
DOT1-like histone H3K79 methyltransferase
GO Process (3)
GO Function (3)
GO Component (0)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Homo sapiens
PREY
MYO1C
MMI-beta, MMIb, NMI, myr2
myosin IC
GO Process (10)
GO Function (2)
GO Component (14)
Gene Ontology Biological Process
- Fc-gamma receptor signaling pathway involved in phagocytosis [TAS]
- innate immune response [TAS]
- membrane organization [TAS]
- positive regulation of cell migration [IMP]
- positive regulation of cell migration by vascular endothelial growth factor signaling pathway [IMP]
- positive regulation of protein targeting to membrane [IMP]
- positive regulation of vascular endothelial growth factor signaling pathway [IMP]
- protein targeting [IDA]
- protein targeting to membrane [IDA]
- regulation of tight junction assembly [IMP]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
- basal plasma membrane [IDA]
- cytoplasm [IDA]
- cytosol [TAS]
- extracellular vesicular exosome [IDA]
- filamentous actin [IDA]
- lateral plasma membrane [IDA]
- membrane [IDA]
- membrane raft [IDA]
- microvillus [IDA]
- mitochondrion [IDA]
- nucleoplasm [IDA]
- plasma membrane [IDA]
- stress fiber [IDA]
- unconventional myosin complex [TAS]
Homo sapiens
Affinity Capture-MS
An interaction is inferred when a bait protein is affinity captured from cell extracts by either polyclonal antibody or epitope tag and the associated interaction partner is identified by mass spectrometric methods.
Publication
Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Targeting vulnerabilities of cancer cells by inhibiting key regulators of cell proliferation or survival represents a promising way to overcome resistance to current therapies. In breast cancer (BC), resistance to endocrine therapy results from constitutively active or aberrant estrogen receptor alpha (ER?) signaling to the genome. Targeting components of the ER? pathway in these tumors represents, therefore, a rational way ... [more]
Breast Cancer Res Dec. 18, 2021; 24(1);52 [Pubmed: 35850772]
Throughput
- Low Throughput
Curated By
- BioGRID